Compare LESL & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LESL | XBIO |
|---|---|---|
| Founded | 1963 | N/A |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 8.2M |
| IPO Year | 2020 | N/A |
| Metric | LESL | XBIO |
|---|---|---|
| Price | $1.79 | $3.42 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $2.54 | N/A |
| AVG Volume (30 Days) | ★ 161.0K | 15.0K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,241,915,000.00 | N/A |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | $2.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $1.90 |
| 52 Week High | $6.92 | $13.93 |
| Indicator | LESL | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 67.65 | 61.70 |
| Support Level | $1.51 | $2.88 |
| Resistance Level | $1.99 | $3.60 |
| Average True Range (ATR) | 0.17 | 0.21 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 69.07 | 72.56 |
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products, including chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company serves residential pool, residential spa, professional pool, and commercial pool consumers and markets its products through over 1,000 company-operated locations in 39 states and e-commerce websites, operating only in the United States. It operates mainly in the pool and spa aftermarket industry and offers regularly purchased, non-discretionary maintenance items, along with installation and repair services for pool and spa equipment.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.